The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.

MedStar author(s):
Citation: Journal of Clinical Lipidology. 13(5):754-761, 2019 Sep - Oct.PMID: 31427271Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Atherosclerosis/dt [Drug Therapy] | *Atherosclerosis/ec [Economics] | *Cardiovascular Diseases/ec [Economics] | *Cost of Illness | *Diabetes Mellitus/ec [Economics] | *Hydroxymethylglutaryl-CoA Reductase Inhibitors/ec [Economics] | *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use] | *Hypertriglyceridemia/ec [Economics] | Adult | Aged | Female | Health Care Costs | Humans | Male | Middle Aged | United States/ep [Epidemiology]Year: 2019ISSN:
  • 1876-4789
Name of journal: Journal of clinical lipidologyAbstract: BACKGROUND: Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.CONCLUSION: In US adults on statins and at high risk for CVD, the health care costs associated with HTG are substantial.Copyright (c) 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.METHODS: We estimated population sizes and annual health care costs among US adults aged >=45 years with diabetes or CVD taking statin therapy with normal triglycerides (TGs) defined as TG < 150 mg/dL compared with those with HTG defined as TG >= 150 mg/dL. Population sizes were estimated from the 2007-2014 National Health and Nutrition Examination Surveys. Adjusted mean total annual health care costs in 2015 US dollars were estimated using the Optum Research Database. The annual total health care cost burden was estimated by multiplying the population size by the mean annual total incremental health care costs overall and within subgroups.OBJECTIVE: We estimated the HTG-related health care cost burden among US adults with CVD or diabetes taking statin therapy.RESULTS: There were 6.2 (95% confidence interval [CI], 5.4 - 7.1) million and 12.0 (95% CI, 11.1 - 12.9) million US adults aged >=45 years with diabetes and/or CVD on statin therapy with TG >= 150 mg/dL and TG < 150 mg/dL, respectively. The mean adjusted incremental total one-year health care costs in adults with TG >= 150 mg/dL compared with those with TG < 150 mg/dL was All authors: Bress AP, Case BC, Fan W, Granowitz CB, Herrick JS, Hull M, Kolm P, Philip S, Toth PP, Weintraub WS, Wong NDOriginally published: Journal of Clinical Lipidology. 2019 Jul 20Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-08-27
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31427271 Available 31427271

BACKGROUND: Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.

CONCLUSION: In US adults on statins and at high risk for CVD, the health care costs associated with HTG are substantial.

Copyright (c) 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.

METHODS: We estimated population sizes and annual health care costs among US adults aged >=45 years with diabetes or CVD taking statin therapy with normal triglycerides (TGs) defined as TG < 150 mg/dL compared with those with HTG defined as TG >= 150 mg/dL. Population sizes were estimated from the 2007-2014 National Health and Nutrition Examination Surveys. Adjusted mean total annual health care costs in 2015 US dollars were estimated using the Optum Research Database. The annual total health care cost burden was estimated by multiplying the population size by the mean annual total incremental health care costs overall and within subgroups.

OBJECTIVE: We estimated the HTG-related health care cost burden among US adults with CVD or diabetes taking statin therapy.

RESULTS: There were 6.2 (95% confidence interval [CI], 5.4 - 7.1) million and 12.0 (95% CI, 11.1 - 12.9) million US adults aged >=45 years with diabetes and/or CVD on statin therapy with TG >= 150 mg/dL and TG < 150 mg/dL, respectively. The mean adjusted incremental total one-year health care costs in adults with TG >= 150 mg/dL compared with those with TG < 150 mg/dL was 730 (95% CI, 160 - 320). This leads to a projected annual incremental cost burden associated with HTG in patients with diabetes or CVD on statins of 0.7 billion (95% CI, .8 B - 4.6 B).

English

Powered by Koha